Physician profile
Antonio P Reyes
NPI 1861503427
$6,491.38
in general payments reported to CMS, 2019-2025
27 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $796 · 2021: $1,063 · 2022: $762 · 2023: $1,017 · 2024: $997 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,111.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,535.63 | 2019-2025 | |
| Amgen INC. | $861.99 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $642.84 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $594.82 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $527.93 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $287.99 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $272.33 | 2020-2024 | Camzyos, Eliquis |
| Medtronic, INC. | $241.88 | 2021-2025 | Linq II |
| Lexicon Pharmaceuticals, INC. | $178.58 | 2023-2024 | Inpefa |
| Abbott Laboratories | $169.34 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $142.32 | 2021-2025 | Verquvo |
| Impulse Dynamics (USA) INC. | $140.24 | 2022-2023 | Optimizer |
| Philips North America LLC | $125.71 | 2022-2024 | (5044) Mcot |
| Braemar Manufacturing, LLC | $107.15 | 2019 | |
| Scpharmaceuticals INC. | $99.44 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $79.28 | 2023-2024 | |
| Boston Scientific Corporation | $78.75 | 2019-2024 | Watchman Flx |
| Itamar Medical INC | $76.22 | 2022-2024 | Watchpatone |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.92 | 2019-2024 | Lifevest |
| Lantheus Medical Imaging, INC. | $61.92 | 2019-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $43.08 | 2021-2023 | Arcalyst |
| Novo Nordisk INC | $35.55 | 2024 | Ozempic, Wegovy |
| Regeneron Healthcare Solutions, INC. | $30.58 | 2019 | |
| Beckman Coulter, INC. | $28.63 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.43 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.50 | 2023 | Xarelto |
| Esperion Therapeutics, INC. | $15.33 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.